Cited 152 times in
Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김건홍 | - |
dc.contributor.author | 서진석 | - |
dc.contributor.author | 양재문 | - |
dc.contributor.author | 허용민 | - |
dc.date.accessioned | 2015-04-23T16:29:38Z | - |
dc.date.available | 2015-04-23T16:29:38Z | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 0142-9612 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/100684 | - |
dc.description.abstract | We investigated the synergism between shRNAs against Bcl-xL and doxorubicin (DOX) using aptamer-conjugated polyplexes (APs) in combination cancer therapy. Synergistic and selective cancer cell death was achieved by AP-mediated co-delivery of very small amounts of DOX and Bcl-xL-specific shRNA, which simultaneously activated an intrinsic apoptotic pathway. A branched polyethyleneimine (PEI) was grafted to polyethylene glycol (PEI-PEG) to serve as a vehicle for shRNA delivery, and its surface was further conjugated with an anti-PSMA aptamer (APT) for the selective delivery of APs to prostate cancer cells that express prostate-specific membrane antigens (PSMA) on their cell surface. The APs were finally obtained after intercalation of DOX to form shRNA/PEI-PEG-APT/DOX conjugates. Cell viability assays and FACS analysis of GFP expression against PC3 (PSMA deficient) and LNCaP (PSMA overexpressed) cells demonstrated that the synthesized APs inhibited the growth of PSMA-abundant prostate cancer cells with strong cell selectivity. Consequently, IC(50) values of APs loaded with both DOX and shRNA were approximately 17-fold less than those for the simple mixture of shRNA plus drug (shRNA/Lipofectamine + DOX). These results suggest that AP-mediated co-delivery of an anti-cancer drug and shRNA against Bcl-xL may widen the therapeutic window and allow for the selective destruction of cancer cells. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 4592~4599 | - |
dc.relation.isPartOf | BIOMATERIALS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Antibiotics, Antineoplastic*/chemistry | - |
dc.subject.MESH | Antibiotics, Antineoplastic*/pharmacology | - |
dc.subject.MESH | Antibiotics, Antineoplastic*/therapeutic use | - |
dc.subject.MESH | Aptamers, Nucleotide*/chemistry | - |
dc.subject.MESH | Aptamers, Nucleotide*/pharmacology | - |
dc.subject.MESH | Aptamers, Nucleotide*/therapeutic use | - |
dc.subject.MESH | Cell Death/drug effects* | - |
dc.subject.MESH | Cell Line, Tumor | - |
dc.subject.MESH | Doxorubicin*/chemistry | - |
dc.subject.MESH | Doxorubicin*/pharmacology | - |
dc.subject.MESH | Doxorubicin*/therapeutic use | - |
dc.subject.MESH | Drug Carriers/chemistry | - |
dc.subject.MESH | Drug Carriers/metabolism | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Materials Testing | - |
dc.subject.MESH | Polyethylene Glycols/chemistry | - |
dc.subject.MESH | Polyethylene Glycols/metabolism | - |
dc.subject.MESH | Polyethyleneimine/chemistry | - |
dc.subject.MESH | Polyethyleneimine/metabolism | - |
dc.subject.MESH | Prostatic Neoplasms/drug therapy* | - |
dc.subject.MESH | RNA, Small Interfering*/genetics | - |
dc.subject.MESH | RNA, Small Interfering*/metabolism | - |
dc.subject.MESH | bcl-X Protein*/genetics | - |
dc.subject.MESH | bcl-X Protein*/therapeutic use | - |
dc.title | Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Biochemistry & Molecular Biology (생화학, 분자생물학) | - |
dc.contributor.googleauthor | Eunjung Kim | - |
dc.contributor.googleauthor | Yukyung Jung | - |
dc.contributor.googleauthor | Hyangtae Choi | - |
dc.contributor.googleauthor | Jaemoon Yang | - |
dc.contributor.googleauthor | Jin-Suck Suh | - |
dc.contributor.googleauthor | Yong-Min Huh | - |
dc.contributor.googleauthor | Kunhong Kim | - |
dc.contributor.googleauthor | Seungjoo Haam | - |
dc.identifier.doi | 10.1016/j.biomaterials.2010.02.030 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00289 | - |
dc.contributor.localId | A01916 | - |
dc.contributor.localId | A04359 | - |
dc.contributor.localId | A02315 | - |
dc.relation.journalcode | J00312 | - |
dc.identifier.eissn | 1878-5905 | - |
dc.identifier.pmid | 20206379 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0142961210002590 | - |
dc.subject.keyword | Combination cancer therapy | - |
dc.subject.keyword | Co-delivery | - |
dc.subject.keyword | Aptamer | - |
dc.subject.keyword | Doxorubicin | - |
dc.subject.keyword | Bcl-xL shRNA | - |
dc.contributor.alternativeName | Kim, Kun Hong | - |
dc.contributor.alternativeName | Suh, Jin Suck | - |
dc.contributor.alternativeName | Yang, Jae Moon | - |
dc.contributor.alternativeName | Huh, Yong Min | - |
dc.contributor.affiliatedAuthor | Kim, Kun Hong | - |
dc.contributor.affiliatedAuthor | Suh, Jin Suck | - |
dc.contributor.affiliatedAuthor | Huh, Yong Min | - |
dc.contributor.affiliatedAuthor | Yang, Jae Moon | - |
dc.citation.volume | 31 | - |
dc.citation.number | 16 | - |
dc.citation.startPage | 4592 | - |
dc.citation.endPage | 4599 | - |
dc.identifier.bibliographicCitation | BIOMATERIALS, Vol.31(16) : 4592-4599, 2010 | - |
dc.identifier.rimsid | 37746 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.